Legacy Capital Wealth Partners LLC Purchases 20,211 Shares of GSK plc (NYSE:GSK)

Legacy Capital Wealth Partners LLC raised its stake in shares of GSK plc (NYSE:GSK - Free Report) by 103.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,769 shares of the pharmaceutical company's stock after buying an additional 20,211 shares during the quarter. Legacy Capital Wealth Partners LLC's holdings in GSK were worth $1,626,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the stock. Mesirow Financial Investment Management Inc. grew its holdings in GSK by 2.0% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company's stock valued at $682,000 after buying an additional 323 shares in the last quarter. Oxbow Advisors LLC grew its holdings in shares of GSK by 3.3% in the third quarter. Oxbow Advisors LLC now owns 140,735 shares of the pharmaceutical company's stock valued at $5,753,000 after purchasing an additional 4,430 shares in the last quarter. Assetmark Inc. grew its holdings in shares of GSK by 137.2% in the third quarter. Assetmark Inc. now owns 19,795 shares of the pharmaceutical company's stock valued at $809,000 after purchasing an additional 11,448 shares in the last quarter. Verdence Capital Advisors LLC grew its holdings in shares of GSK by 25.9% in the third quarter. Verdence Capital Advisors LLC now owns 6,823 shares of the pharmaceutical company's stock valued at $279,000 after purchasing an additional 1,402 shares in the last quarter. Finally, United Bank grew its holdings in shares of GSK by 7.3% in the third quarter. United Bank now owns 25,785 shares of the pharmaceutical company's stock valued at $1,054,000 after purchasing an additional 1,760 shares in the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at GSK

In other GSK news, major shareholder Plc Gsk acquired 2,791,930 shares of the stock in a transaction that occurred on Friday, September 27th. The stock was bought at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the purchase, the insider now directly owns 16,775,691 shares in the company, valued at $134,205,528. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.00% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Guggenheim lowered shares of GSK from a "buy" rating to a "neutral" rating in a report on Thursday, October 31st. Barclays upgraded GSK to a "hold" rating in a research report on Tuesday, August 27th. Finally, Argus upgraded GSK to a "strong-buy" rating in a research report on Wednesday, August 7th. Five investment analysts have rated the stock with a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, GSK has a consensus rating of "Moderate Buy" and a consensus price target of $50.00.

GSK Trading Down 1.0 %

Shares of NYSE:GSK traded down $0.37 on Friday, hitting $36.29. 8,866,773 shares of the company's stock were exchanged, compared to its average volume of 6,274,321. GSK plc has a 12 month low of $33.89 and a 12 month high of $45.92. The stock has a market capitalization of $75.21 billion, a price-to-earnings ratio of 23.56, a price-to-earnings-growth ratio of 1.38 and a beta of 0.66. The business's 50 day simple moving average is $39.95 and its two-hundred day simple moving average is $40.91. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be given a dividend of $0.3928 per share. This represents a $1.57 annualized dividend and a dividend yield of 4.33%. This is an increase from GSK's previous quarterly dividend of $0.38. The ex-dividend date of this dividend is Friday, November 15th. GSK's dividend payout ratio (DPR) is 98.70%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.